Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset.


Journal

Intensive care medicine
ISSN: 1432-1238
Titre abrégé: Intensive Care Med
Pays: United States
ID NLM: 7704851

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 27 05 2020
accepted: 24 07 2020
pubmed: 12 8 2020
medline: 18 9 2020
entrez: 12 8 2020
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is creating an unprecedented healthcare crisis. Understanding the determinants of mortality is crucial to optimise intensive care unit (ICU) resource use and to identify targets for improving survival. In a multicentre retrospective study, we included 379 COVID-19 patients admitted to four ICUs between 20 February and 24 April 2020 and categorised according to time from disease onset to ICU admission. A Cox proportional-hazards model identified factors associated with 28-day mortality. Median age was 66 years (53-68) and 292 (77%) were men. The main comorbidities included obesity and overweight (67%), hypertension (49.6%) and diabetes (30.1%). Median time from disease onset (i.e., viral symptoms) to ICU admission was 8 (6-11) days (missing for three); 161 (42.5%) patients were admitted within a week of disease onset, 173 (45.6%) between 8 and 14 days, and 42 (11.1%) > 14 days after disease onset; day 28 mortality was 26.4% (22-31) and decreased as time from disease onset to ICU admission increased, from 37 to 21% and 12%, respectively. Patients admitted within the first week had higher SOFA scores, more often had thrombocytopenia or acute kidney injury, had more limited radiographic involvement, and had significantly higher blood IL-6 levels. Age, COPD, immunocompromised status, time from disease onset, troponin concentration, and acute kidney injury were independently associated with mortality. The excess mortality in patients admitted within a week of disease onset reflected greater non-respiratory severity. Therapeutic interventions against SARS-CoV-2 might impact different clinical endpoints according to time since disease onset.

Identifiants

pubmed: 32780165
doi: 10.1007/s00134-020-06202-3
pii: 10.1007/s00134-020-06202-3
pmc: PMC7417780
doi:

Substances chimiques

Interleukin-6 0
Troponin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1714-1722

Références

JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Kidney Int. 2015 Jan;87(1):62-73
pubmed: 25317932
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Infect Dis. 2020 Jun 16;222(1):26-33
pubmed: 32339231
Cytokine Growth Factor Rev. 2020 Jun;53:38-42
pubmed: 32360420
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Cancer Metastasis Rev. 2020 Jun;39(2):337-340
pubmed: 32385712
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Virol Sin. 2020 Jun;35(3):266-271
pubmed: 32125642
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Mol Med. 2020 May 7;26(1):42
pubmed: 32380958
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Lancet Respir Med. 2019 Feb;7(2):173-186
pubmed: 30529232
Lancet. 2015 May 2;385(9979):1778-1788
pubmed: 25943942
Biomed Pharmacother. 2020 Jul;127:110195
pubmed: 32361161
Lancet. 2020 May 16;395(10236):1544-1545
pubmed: 32380044
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Ann Am Thorac Soc. 2020 Jul;17(7):839-846
pubmed: 32255382

Auteurs

Elie Azoulay (E)

Service de Médecine Intensive et Réanimation, Hôpital Saint-Louis, APHP, Paris, France. elie.azoulay@aphp.fr.
Université de Paris, Paris, France. elie.azoulay@aphp.fr.

Muriel Fartoukh (M)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Tenon, APHP, Paris, France.

Michael Darmon (M)

Service de Médecine Intensive et Réanimation, Hôpital Saint-Louis, APHP, Paris, France.
Université de Paris, Paris, France.

Guillaume Géri (G)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Ambroise Paré, APHP, Paris, France.

Guillaume Voiriot (G)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Tenon, APHP, Paris, France.

Thibault Dupont (T)

Service de Médecine Intensive et Réanimation, Hôpital Saint-Louis, APHP, Paris, France.
Université de Paris, Paris, France.

Lara Zafrani (L)

Service de Médecine Intensive et Réanimation, Hôpital Saint-Louis, APHP, Paris, France.
Université de Paris, Paris, France.

Lola Girodias (L)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Ambroise Paré, APHP, Paris, France.

Vincent Labbé (V)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Tenon, APHP, Paris, France.

Martin Dres (M)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, APHP, Paris, France.

Alexandra Beurton (A)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, APHP, Paris, France.

Antoine Vieillard-Baron (A)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Ambroise Paré, APHP, Paris, France.

Alexandre Demoule (A)

Université de Paris, Paris, France.
Service de Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, APHP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH